Cargando…

The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy

Immunotherapy as a treatment for cancer is a growing field of endeavor but reports of success have been limited for epithelial ovarian cancer. Overcoming the challenges to developing more effective therapeutic approaches lies in a better understanding of the factors in cancer cells and the surroundi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodriguez, Galaxia M., Galpin, Kristianne J. C., McCloskey, Curtis W., Vanderhyden, Barbara C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116043/ https://www.ncbi.nlm.nih.gov/pubmed/30042343 http://dx.doi.org/10.3390/cancers10080242

Ejemplares similares

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
por: McCloskey, Curtis W., et al.
Publicado: (2018)

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
por: Farokhi Boroujeni, Salar, et al.
Publicado: (2023)

LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model
por: Mehdi, Sadia, et al.
Publicado: (2020)

The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool for Ovarian Cancer Immunotherapy Research
por: Rodriguez, Galaxia M., et al.
Publicado: (2022)

Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer
por: Cook, David P., et al.
Publicado: (2023)

Transcriptional heterogeneity of stemness phenotypes in the ovarian epithelium
por: Carter, Lauren E., et al.
Publicado: (2021)

A New Spontaneously Transformed Syngeneic Model of High-Grade Serous Ovarian Cancer with a Tumor-Initiating Cell Population
por: McCloskey, Curtis W., et al.
Publicado: (2014)

The influence of microenvironment on tumor immunotherapy
por: Zhang, Jieying, et al.
Publicado: (2019)

Tissue‐specific tumor microenvironments influence responses to immunotherapies
por: Oliver, Amanda J, et al.
Publicado: (2019)

Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment
por: Surendran, Abera, et al.
Publicado: (2023)

Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment
por: Xu, Yan
Publicado: (2018)

Non-canonical WNT5a regulates Epithelial-to-Mesenchymal Transition in the mouse ovarian surface epithelium
por: Abedini, Atefeh, et al.
Publicado: (2020)

The significance of ovarian fibrosis
por: Landry, David A., et al.
Publicado: (2020)

Conventional DNA-Damaging Cancer Therapies and Emerging cGAS-STING Activation: A Review and Perspectives Regarding Immunotherapeutic Potential
por: Lewicky, Jordan D., et al.
Publicado: (2023)

Transcriptional census of epithelial-mesenchymal plasticity in cancer
por: Cook, David P., et al.
Publicado: (2022)

Non-immune Cell Components in the Gastrointestinal Tumor Microenvironment Influencing Tumor Immunotherapy
por: Li, Zhengshuo, et al.
Publicado: (2021)

Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy
por: Aboelella, Nada S., et al.
Publicado: (2021)

Animal models of ovarian cancer
por: Vanderhyden, Barbara C, et al.
Publicado: (2003)

Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy
por: Lin, Yi, et al.
Publicado: (2022)

Immunotherapy Advances for Epithelial Ovarian Cancer
por: Hartnett, Erin G., et al.
Publicado: (2020)

PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming
por: Feng, Yan, et al.
Publicado: (2020)

17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo
por: Laviolette, Laura A, et al.
Publicado: (2014)

CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress
por: Shi, Jun, et al.
Publicado: (2019)

Role of the tumor immune microenvironment in tumor immunotherapy
por: Zhou, Changsheng, et al.
Publicado: (2022)

Understanding the tumor microenvironment for effective immunotherapy
por: Sadeghi Rad, Habib, et al.
Publicado: (2020)

Vascular Microenvironment, Tumor Immunity and Immunotherapy
por: Lamplugh, Zachary, et al.
Publicado: (2021)

Tumor microenvironment and immunotherapy of oral cancer
por: Liu, Chang, et al.
Publicado: (2022)

Immunotherapy: Reshape the Tumor Immune Microenvironment
por: LV, Bingzhe, et al.
Publicado: (2022)

Immunotherapy of targeting MDSCs in tumor microenvironment
por: Sui, Hongshu, et al.
Publicado: (2022)

Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy
por: Xu, Tianyue, et al.
Publicado: (2022)

Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design
por: Li, Yan-Ruide, et al.
Publicado: (2023)

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
por: Oliver, Amanda J., et al.
Publicado: (2018)

Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
por: Economopoulou, Panagiota, et al.
Publicado: (2020)

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
por: Peng, Shaojun, et al.
Publicado: (2021)

Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses
por: Deng, Ruiyi, et al.
Publicado: (2022)

Tumor microenvironment responsive metal nanoparticles in cancer immunotherapy
por: Yang, Rou, et al.
Publicado: (2023)

Driving Immune Responses in the Ovarian Tumor Microenvironment
por: Ning, Franklin, et al.
Publicado: (2021)

Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma
por: Sung, Pi-Lin, et al.
Publicado: (2015)

Shifting the Soil: Metformin Treatment Decreases the Protumorigenic Tumor Microenvironment in Epithelial Ovarian Cancer
por: Taylor, Sarah E., et al.
Publicado: (2022)

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression
por: Barger, Carter J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_96hn8vqr7e25rogbuf5s66rqbj